RBCG VACCINE SECRETING SARS-COV-2 ANTIGENS (rBCG vaccine project)
- Funded by Institut Pasteur International Network (IPIN)
- Total publications:218 publications
Grant number: Unknown
Grant search
Key facts
Disease
COVID-19Funder
Institut Pasteur International Network (IPIN)Principal Investigator
PendingResearch Location
N/ALead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Subject
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Mycobacterium bovis BCG is a live attenuated vaccine that is used since almost 100 years for the vaccination against tuberculosis, with a solid safety record in billions of immunocompetent individuals. The aim of the project is to construct recombinant BCG strains that express viral protein(s) of the SARS-CoV-2 virus in fusion with the 6 kD early secreted antigenic target (ESAT-6), secreted by the type VII secretion systems.
Publicationslinked via Europe PMC
Last Updated:3 days ago
View all publications at Europe PMC